Histone deacetylases (HDACs) 
Introduction
Chromatin organization plays a key role in the control of gene expression. In the nucleosome, DNA is wrapped around a core of positively charged proteins: the histones [1] . Post [2] . [3] .
Acetylation at ⑀-amino groups of conserved lysine residues influences the activity of several proteins including histones, transcription factors and cytoskeletal elements. Lysines acetylation is controlled by the antagonistic engagement of two families of enzymes: the histone acetyltransferases (HATs) and the histone deacetylases (HDACs). On histones, lysines acetylation weakens the interaction of their positively charged tails with the negative

• Introduction
The 18 human HDACs can be grouped into four different classes, based on sequence homologies to the yeast orthologues Rpd3, Hda1 and Sir2 (Fig. 1) . Class I includes HDAC1, -2, -3 and -8, which show homologies with Rpd3. Class II comprises HDAC4, -5, -6, -7, -9, -10 2, 3, 4, 5, 6 and 7 , also known as silent information regulators (SIR) and are homologous to Sir2 in yeast. Finally, because HDAC11 shares sequence similarities with both classes I and II it forms, alone, the class IV [4] [5] [6] . Classes I, II and IV act with a zinc-dependent mechanism, whereas class III activity is NAD ϩ dependent and is not affected by the classical HDAC inhibitors. Classes I and II HDACs share homology in the catalytic motif, but diverge for the N-terminal region, which is extended only in class II [7] . 
HDACs form high molecular weight complexes with different corepressors, which cooperate in silencing the transcription of several genes involved in various cancer-related functions, such as proliferation, migration, angiogenesis and differentiation. In
General concepts on class IIa HDACs
Regulation of subcellular localization
To negatively influence the transcriptional process class IIa HDACs need to be in the nucleus, where they associate in macromolecular complexes [8, 9] . An important strategy for restricting class IIa repressive activities is fulfilled by monitoring their subcellular localization. Class IIa HDACs carry both a nuclear localization signal (NLS) and a nuclear export signal (NES) that, once properly exposed, control the enzyme distribution in the two compartments [10, 11] . Inhibition of the Exportin 1 receptor (CRM-1) nuclear transporter by leptomycin B treatment determines the nuclear accumulation of class IIa HDACs, suggesting that these proteins shuttle continuously in and out the nucleus [12] [13] [14] . Several extracellular stimuli, through the activation of different kinases, are able to alter the balance between nuclear import and export of these repressors. Phosphorylation takes place on different serine residues, located in the amino-terminal region, which act as docking sites for 14-3-3 proteins binding [13] [14] [15] [16] . Consequently, mutations of these residues into alanines relieve class IIa HDACs from kinases control, generating a super-repressive enzyme [12, 17, 18] .
The interaction with 14-3-3 proteins influences class IIa subcellular localization through different mechanisms [19] [20] [21] . Binding of 14-3-3 proteins can mask the NLS sequence and thereby preventing the interaction with importin-␣ [13] . Alternatively, these interactions could promote a conformational change and the consequent exposition of the NES in the carboxyterminal region that favours nuclear export [22] .
In [9] . In this circumstance, the interaction involves the carboxy-terminal domain as a docking site for the recruitment of the class I HDAC (Fig. 2) .
Finally, class IIa can interact with H3K9 methyltransferase SUV39H1 and HP1, structural components of heterochromatin that are essential for compact DNA packaging [26] . These additional players with nucleosomal remodelling properties point to the existence of complex molecular machineries devote to the orchestration of the epigenetic changes.
An additional peculiar feature of the amino-terminal region of class IIa HDACs is the presence of a glutamine rich domain (aa 62-129) [77]. This domain folds in straight ␣-helix that assemble in tetramers. It has been proposed that glutamine-rich domain could modulate dynamic protein-protein interactions thus possibly justifying the long list of class IIa HDACs interactors.
Catalytic activity
Although in vertebrates HDACs class IIa display catalytic sites similar to class I, surprisingly, they are inefficient enzymes and only a weak deacetylase activity can be measured in vitro on acetylated lysines [9, 78] 
Class IIa HDAC orthologues in model organisms
Class IIa HDAC orthologues have been described in Drosophlia melanogaster and Caenorhabditis elegans. These orthologues conserve the critical tyrosine in the HDAC domain and possess an elevated deacetylase activity [7, 82] [96, 97] . Deregulated expression of this enzyme was observed in hepatocellular carcinoma where its levels are increased because of the lack of two different miRNAs: miR-1 and miR-22 [98, 99] . Also in this context the down-regulation of HDAC4 reduces the growth rate [99] . miR-1 dysfunction and HDAC4 up-regulation, have been reported also in lung cancer cells [100] . [102, 103] [104, 105] [109] . [111] .
As explained earlier, HDAC4 levels are also under the control of the ubiquitin-proteasome system. Growth factors can augment HDAC4 levels by suppressing its poly-ubiquitination. In this case, the molecular switch seems to be represented by GSK3␤ [49]. Not surprisingly, cancer cells have lost this regulation and HDAC4 levels are maintained elevated also in the absence of growth factors. Surprisingly, whereas different mechanisms are described to affect HDAC4 expression in cancer cells little is known about the contribution of various oncogenic signalling pathways on its subcellular localization. Although preliminary studies suggested that oncogenic Ras could promote HDAC4 nuclear accumulation [101], how this impact on Ras-mediated transformation is unknown. In addition, HDAC4 could contribute to cancer development independently from its chromatin attitude. This enzyme is able to associate with HIF1-␣, a critical factor activated by hypoxia that plays an important role in tumour progression
. The binding of HDAC4 protects HIF1-␣ from degradation and the use of HDACs inhibitors causes its acetylation and down-regulation [102]. Interestingly, other class IIa HDACs are able to bind HIF1-␣ and this binding seems to increase its transcriptional activity
Another context in which HDAC5 seems to carry out a regulatory function is the skeletal muscle. This repressor acts by blocking the differentiation of myoblasts to myotubes. The suppressive effect was the result of the inhibitory activity against MEF2 transcription factors [106]. Interestingly, the lack of a specific class IIa HDACs does not affect the development of the skeletal muscle suggesting, as in the heart, the possible redundant role for class IIa HDACs. In addition, HDAC5 is also involved in controlling osteoblastic differentiation. In this case its action is to tether RUNX2, a critical transcription factor for osteoblast maturation [107]. In particular, upon TGF-␤ stimulation, HDAC5 can exert its function by forming a repressive complex with RUNX2 and SMAD3, which promotes RUNX2 degradation [64,108]. Another piece of the complex puzzle controlling osteoblastic differentiation is provided by miR-2861, which targets HDAC5 and promotes its down-regulation at post-transcriptional level
HDAC5 acts also as a central player in the regulation of the angiogenetic process. Silencing of HDAC5 can increase sprout length and endothelial migration, whereas the silencing of two other class IIa HDACs such as HDAC7 and HDAC9 promoted the opposite effect [110]. The anti-angiogenic behaviour of HDAC5 is independent from MEF2 and affects the secretion of FGF2 and Slit2. Moreover, VEGF stimulation of HUVEC cells promotes HDAC5 phosphorylation and nuclear export thereby stimulating MEF2 dependent transcription and in vitro angiogenesis
HDAC5 and cancer
Although the contribution of HDAC5 to the control of angiogenesis is clearly a cancer-related process, there several other studies pointing out specific contributions of this deacetylase in cell growth and proliferation [112] . Initial observations based on overexpression studies described HDAC5 as a negative regulator of cell proliferation in different cancer cell lines [113] . Following this initial report it has also been found that HDAC5 repressed cyclin D3 promoter in fibroblast [114] . Conversely, HDAC5 could participate in p14 repression through the association with TBX3 in breast cancer cells, although detailed molecular data are lacking [115] . Recently, it was observed that HDAC5 plays an important role in neural stem cell proliferation [116, 117] [125] .
Silencing of HDAC7 in the breast cancer cell line MCF7 negatively influences 17-␤-estradiol (E2)-mediated repression of RPRM, as well as that of other E2-repressed genes such as ENC1, NEDD9, OPG, CXCR4 and CERK. Upon treatment with E2, the estrogen receptor ER-␣ interacts with HDAC7 and mediates its recruitment to the RPRM promoter. The repressive activity of HDAC7 on RPRM is independent from its catalytic function. Also hormone binding to the AR induces stabilization and nuclear transfer of HDAC7. Nuclear HDAC7 represses AR-target genes transcription, and, here again, this function is mostly independent from the catalytic domain [72].
HDAC7 and cancer
The involvement of HDAC7 in the control of proliferation and angiogenesis is a smoking gun for its role in cancer. Not surprisingly, emerging evidence implicate an association of HDAC7 with cancer progression. High level of cytoplasmic HDAC7 was reported in pancreatic cancer patients [126] . Similarly, in children with acute lymphobastic leukaemia (ALL) high levels of HDAC7 and HDAC9 expression are associated with poor prognosis [127] . Interestingly, because in various cancer and normal cell lines HDAC7 expression was found to be specifically down-regulated by HDAC inhibitors (HDIs) [128, 129] , tumours with high levels of HDAC7 could be more sensitive to HDIs treatment. For example, in cancer cells the repressive influence of HDAC7 is required for HIF-1-mediated cyclin D1 down-regulation [130] . In their study, the authors suggested that chemoresistance associated to HIF-1 expression might be dependent on the HDAC7-mediated repression on cyclin D1 expression [130] . In this model, cotreatment with HDIs and classical chemotherapeutics can overcome the drug-resistance phenotype.
It is important to note that HDAC7 is also implicated in the control of apoptosis in T cells, via the repression of Nur77 expression [119] . In cutaneous T cell lymphoma (CTCL), HDIs inhibit HDAC7 at multiple levels, including mRNA expression. HDAC7 inhibition permits Nur77 expression and its translocation to the mitochondria. Here, Nur77 triggers the intrinsic cell death pathway and synergizes with the Bcl-2/Bcl-xL antagonist ABT-737 to promote CTCL apoptosis [131] .
During apoptosis HDAC7 is under the control of caspase-8. Processing by caspase-8 abolishes the transcription repression activity of HDAC7 thus, promoting Nur77 expression [132] .
Very recently, using a trasposon-mediated mutagenesis approach in mice, HDAC7 has been identified as a cancer-related gene [133] . In conclusion, HDAC7 seems to contribute at several aspects of cancer, from its development up to drug resistance. Understanding the details of its fine regulation/dysregulation is pivotal to approach translation studies to develop new therapeutic approaches. [134, 135] [134, 136] [138] . More recent studies have unveiled a contribution of HDAC9 in the dendritic growth of cortical neurons [139] . Finally, HDAC9 seems important in the regulation of FOXP3, a transcription factor involved in Treg cells functions [140] .
HDAC9 HDAC9 and differentiation
HDAC9 undergoes alternative splicing that gives origin to multiple isoforms, with putative distinct tissue-specific biological activities
. MEF2-interacting transcription repressor/HDACrelated protein (MITR/HDRP) was the first form of HDAC9 to be characterized. This splice variant consists in the N-terminal part of the protein, devoid of the catalytic domain
HDAC9 and cancer
qRT-PCR studies on HDACs in brain tumours have revealed a down-regulation of HDAC9 in glioblastoma, compared to lowgrade astrocytoma and normal brain [141] . By contrast, high levels of HDAC5 and HDAC9 expression are associated with poor survival in medulloblastoma patients [112] . Both HDAC5 and 9 are highly expressed in the group with poorer prognosis, whereas the up-regulation of only one of the two genes gives an intermediate probability of survival. Silencing of HDAC5 or HDAC9 in medulloblastoma cell lines decreased cell growth and induced apoptosis after caspase activation [112] . High levels of mRNA expression for HDAC9 together with HDAC7 were observed also in bone marrow of children with acute lymphoblastic leukaemia, associated with bad tumour prognosis [127] . The 
